Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
Status:
Recruiting
Trial end date:
2021-11-16
Target enrollment:
Participant gender:
Summary
This is the first time PF-07242813 will be given to humans. The purpose of the study is to
evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses
of PF-07242813 in healthy participants and in participants with moderate to severe atopic
dermatitis. An additional goal is to assess the pharmacodynamics of PF-07242813 in
participants with moderate to severe AD, including potential effects on clinical signs and
symptoms.